Inclusion of elderly patients in oncology clinical trials

被引:81
作者
Le Saux, O. [1 ,2 ]
Falandry, C. [3 ,4 ]
Gan, H. K. [5 ,6 ,7 ]
You, B. [1 ,2 ]
Freyer, G. [1 ,2 ]
Peron, J. [1 ,8 ,9 ]
机构
[1] HCL, IC, Dept Med Oncol, Pierre Benite, France
[2] Univ Lyon 1, EMR 3738, Fac Med Lyon Sud, Oullins, France
[3] Ctr Hosp Lyon Sud, Geriatr Oncol Dept, Pierre Benite, France
[4] Univ Lyon, INSERM, UMR 1060, CarMen Biomed Res Lab Cardiovasc Dis Metab Diabet, Oullins, France
[5] Austin Hlth, Med Oncol, Heidelberg, Vic, Australia
[6] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[7] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia
[8] Hosp Civils Lyon, Stat Unit, Pierre Benite, France
[9] Univ Lyon 1, CNRS, UMR 5558, Biometry & Evolutionary Biol Lab, Villeurbanne, France
关键词
geriatric oncology; neoplasms; clinical trials; METASTATIC BREAST-CANCER; GERIATRIC ONCOLOGY; INTERNATIONAL SOCIETY; OLDER PATIENTS; END-POINTS; RELEVANT; IMPACT; WOMEN;
D O I
10.1093/annonc/mdw259
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since the creation of the International Society of Geriatric Oncology, the proportion of phase III trials reporting at least one analysis dedicated to elderly patients has grown (46.7% between 2011 and 2014 versus 19.3% between 2001 and 2004). However, evidence-based data are mostly extracted from subgroup analyses that can only be considered as preliminary evidence.Physicians need clinical trials assessing benefits and harms of treatments to avoid under-treatment or over-treatment of elderly patients. The main objectives of this report were to examine how data regarding elderly oncology patients were presented in medical literature; and to assess the evolution of this presentation between two time periods. All phases I, II and III trials dedicated to the treatment of cancer among elderly patients published between 2001 and 2004 and between 2011 and 2014 were reviewed. All phase III clinical trials assessing cancer treatments among adults in the same periods were also reviewed to evaluate potential subgroup analyses in elderly patients in these studies. Key characteristics of interest were extracted by two investigators before descriptive and comparative analyses were undertaken. A total of 1084 trials were included: 366 and 718 from the first and second time period, respectively. Twenty-seven and 193 of these trials were phase I and II trials dedicated to elderly or frail patients, respectively. A large proportion of phase III trials published between 2011 and 2014 reported at least one analysis dedicated to elderly patients (46.7%) versus 19.3% during the first time period. The use of subgroup analyses of elderly patients in phase III trials was the most frequent source of information. Subgroup analyses were more frequent among trials with industrial funding, trials published in high impact factor journal, intercontinental trials and trials with large sample size. The age threshold defining the elderly subgroup increased over time. Elderly patients have become a topic of interest during the past decade. However, data available are mostly extracted from subgroup analyses, which can only be regarded as preliminary evidence.
引用
收藏
页码:1799 / 1804
页数:6
相关论文
共 23 条
[1]   Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events? [J].
Als-Nielsen, B ;
Chen, WD ;
Gluud, C ;
Kjaergard, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :921-928
[2]   Geriatric oncology: challenges for the new century [J].
Balducci, L .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1741-1754
[3]   Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice? [J].
Bria, Emilio ;
Di Maio, Massimo ;
Cuppone, Federica ;
Nistico, Cecilia ;
Cognetti, Francesco ;
Giannarelli, Diana .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :605-606
[4]   Choosing relevant endpoints for older breast cancer patients in clinical trials: an overview of all current clinical trials on breast cancer treatment [J].
de Glas, N. A. ;
Hamaker, M. E. ;
Kiderlen, M. ;
de Craen, A. J. M. ;
Mooijaart, S. P. ;
van de Velde, C. J. H. ;
van Munster, B. C. ;
Portielje, J. E. A. ;
Liefers, G. J. ;
Bastiaannet, E. .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (03) :591-597
[5]   PUBLICATION BIAS IN CLINICAL RESEARCH [J].
EASTERBROOK, PJ ;
BERLIN, JA ;
GOPALAN, R ;
MATTHEWS, DR .
LANCET, 1991, 337 (8746) :867-872
[6]   Annual report to the Nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment [J].
Edwards, BK ;
Brown, ML ;
Wingo, PA ;
Howe, HL ;
Ward, E ;
Ries, LAG ;
Schrag, D ;
Jamison, PM ;
Jemal, A ;
Wu, XC ;
Friedman, C ;
Harlan, L ;
Warren, J ;
Anderson, RN ;
Pickle, LW .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (19) :1407-1427
[7]  
European Medicines Agency, 2009, E7R1 EUR MED AG
[8]   Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial [J].
Falandry, C. ;
Brain, E. ;
Bonnefoy, M. ;
Mefti, F. ;
Jovenin, N. ;
Rigal, O. ;
Guillem, O. ;
El Kouri, C. ;
Uwer, L. ;
Abadie-Lacourtoisie, S. ;
Cretin, J. ;
Jacquin, J. P. ;
Paraiso, D. ;
Freyer, G. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) :2806-2814
[9]   Are aging biomarkers clinically relevant in oncogeriatrics? [J].
Falandry, Claire ;
Gilson, Eric ;
Rudolph, K. Lenhard .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) :257-265
[10]  
FREEDMAN LS, 1995, CONTROL CLIN TRIALS, V16, P277, DOI 10.1016/0197-2456(95)00048-8